RE:People expecting more bad news postNot there yet and plenty of future options still out there. Especially if you have a few large institutions that will want to unlock all the easy value they can. Right now, it's a value traders dream.
If revs are confirmed, growing and cost cuts get to breakeven, value trader would have a 12 month window for valuation to revert to the mean and make 50-100%. Nothing to sneeze at but only a move from $90 to $1.40 or $2.00. The reversion to comps would be based on a value guy seeing the $90mil to $100mil rev growth, new versions of drugs bolstering margins and revs, and comps at 3x sales; followed by projected breakeven and then $12-15 EBITDA with comps at 17.5x EV/EBITDA. Not hard to see a trade if you're a bold deep value guy, which is why their financial plan needs to be simple and believable. If some PMs a bold value guy, they will make money off a trade like that if mgmt presents a solid plan.